比伐卢定是一种DTI，克服了间接凝血酶抑制剂（如肝素）的许多限制。比伐卢定是一种短效的合成肽，其是有效的，高度特异性的和可逆的凝血酶抑制剂。它抑制循环和结合凝块的凝血酶，同时还抑制凝血酶介导的血小板活化和聚集。比伐卢定具有快速起效和短期半衰期。它不与血浆蛋白（凝血酶除外）或红细胞结合。因此，它具有可预测的抗血栓反应。肝素诱导的血小板减少症/肝素诱导的血栓形成血小板减少综合征（HIT / HITTS）没有风险，不需要结合辅助因子如抗凝血酶，不能激活血小板。这些特征使得比伐卢定成为肝素的理想替代品。

功能

比伐卢定被用作经历经皮腔内冠状动脉血管成形术（PTCA）的不稳定型心绞痛患者的抗凝血剂。 临时使用糖蛋白IIb / IIIa抑制剂（GPI）的比伐卢定被指定用作经皮冠状动脉介入治疗（PCI）患者的抗凝血剂。 Bivalirudin适用于HIT / HITTS接受PCI治疗或有风险的患者。 比伐卢定用于阿司匹林，仅在接受阿司匹林治疗的患者中进行了研究。

规范

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin.It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.

Function

Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI. Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Specification